My first pick this week is Boeing which reported great earnings last week. Analysts where looking for $1.24 a share yet BA handily beat coming in at $1.44 a share. The stock has a P/E of 10 and a PEG of 0.83 and a yield of 1.5%, and that alone makes it very attractive. Right now there is a lot of debate as to whether Boeing can deliver the 787 on time and that has kept pressure on the shares as of late. First off, I do not think it matters if they can deliver the 787 by December or April, the fact of the matter is that Airbus is so far behind, BA has some wiggly room. Boeing also gave a weak 4th quarterly out-look, which hurt shares but with $295 Billion in back-orders EPS is locked for some time. This is one of the holdings of the Vicex Fund which holds a lot of other good "bad" companies. The fund invests 80% of its assets in companies that are considered "socially irresponsible," and has had an average annual return of 18.7% for the last three years, which holds a lot of other good "bad" companies. The fund invests 80% of its assets in companies that are considered "socially irresponsible," and has had an average annual return of 18.7% for the last three years. BA could trade to $100 this week

Conoco Phillips reported third-quarter earnings that were basically in line with the company's recent guide down. With, crude oil over $90 a barrel the company's earnings are being hurt by poor refining margins. Although this may not last long, on Friday Kirk Kerkorian's Tracinda bought a huge stake in the refiner Tesoro, which may indicate that refining margins are going to pick up once again.

For the more speculative traders Longtop Financial (LFT) just came public on Wednesday. LFT offers information technologies to services to China's financial services sector. Longtop is active in two-thirds of China's provinces and the fact that China has a middle class the size of the either population of the United States creates additional demand for such technology.

Also worth looking at is Merck which is breaking out to a 4 year high after reporting great third-quarter earnings and raised guidance for the fourth time this year. Third-quarter profit soared 62% on higher sales of vaccines and drugs for asthma and diabetes, and a lower reserve for product-liability litigation. Also, sales declined for their former star-drug, Zocor, which Merck lost exclusivity last year. This show investors that this decline in market share and has not hurt Merck's bottom line. Merck also boasts a 2.7& yield.

Celgene also made this week's Rocket Stock's list, after reporting earnings last Thursday the CELG traded down almost $6 to $64.22 after missing expectations for revenue and sales but beating EPS. On an adjusted basis, the company earned $124.1 million or 29 cents a share compared to the 28 cents analysts where looking for. When companies beat on the EPS but miss on the revenue it is always a tricky; should you add more to your position or simply wait? In most cases the first day or two investors beat the stock down; those dips should be bought as the company did beat on EPS. In Celgene's case it is also a FED play, if growth is slowing then CELG should rally into that. I see it trading $70 by week's end.

Another small cap metals play which could rocket after a FED rate cut.

NSTK reports on the 29th. I am looking for a major piece of news out of this company. With Dr. Hollander on "board" NSTK is the offers the best risk vs reward in the bio-tech sector. Jim Cramer thinks that if one piece of major news comes NSTK could rally.

FreightCar America has been on a horrible slide ever since it posted sub-par earnings back in July and down some 33% from those July highs RAIL is now worth look. With a short position of 18% leaning on the stock it is no wonder RAIL has had trouble moving but with investors such as Buffet and other large hedge funds investing in the RAIL space shorting such stocks will back fire. My guess is that Buffet is indirectly playing international growth via the rails; it is the safest way for him. RAIL manufactures, rebuilds, repairs and sells freight cars that are used for hauling coal, and other commodities and it seems like a great way to indirectly play the current transition back into the rails. With a $17.50 book value and $1.3 in revenue and ZERO debt look for RAIL to move higher this coming week. Weekly Catalyst: Beaten down repair of rail-road cars is about to move much higher as it sports zero debt and a high book value. Also a great play on the transitional back into rails.